TOFAJAK blocks Janus kinases (JAK), enzymes that play a key role in the signalling pathway of inflammation. This helps control immune responses, reduce joint swelling, and maintain mobility.
Recommended for:
Adults with moderate to severe rheumatoid arthritis
Psoriatic arthritis unresponsive to conventional therapy
Moderate to severe ulcerative colitis
Patients intolerant or unresponsive to methotrexate or other DMARDs
Indicated for the treatment of adults with moderate to severe active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
One tablet (5mg) is taken orally twice a day, with or without food. Dose adjustments may be required based on individual tolerance and coexisting conditions.
Contraindicated in patients with severe infections, pregnancy, liver failure, or active tuberculosis. Side effects may include upper respiratory infections, elevated cholesterol, headache, nausea, and anaemia.
